Aclaris Therapeutics Inc.

AI Score

0

Unlock

2.50
0.02 (0.81%)
At close: Jan 14, 2025, 3:59 PM
2.51
0.60%
After-hours Jan 14, 2025, 04:41 PM EST
undefined%
Bid 2.51
Market Cap 267.01M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.52
PE Ratio (ttm) -4.8
Forward PE n/a
Analyst Buy
Ask 2.58
Volume 2,592,429
Avg. Volume (20D) 2,587,559
Open 2.50
Previous Close 2.48
Day's Range 2.31 - 2.50
52-Week Range 0.95 - 5.17
Beta undefined

About ACRS

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of...

Sector Healthcare
IPO Date Oct 6, 2015
Employees 86
Stock Exchange NASDAQ
Ticker Symbol ACRS

Analyst Forecast

According to 5 analyst ratings, the average rating for ACRS stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 220.64% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Aclaris Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $5.85M, reflecting a -66.7% YoY shrinking and earnings per share of -0.27, making a -10.00% decrease YoY.
1 month ago · Source
+46.18%
Aclaris Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
1 month ago · Source
+53.17%
Aclaris Therapeutics shares are trading higher after the company announced it entered into an exclusive license agreement with Biosion for worldwide rights to BSI-045B. The company announced an $80 million private placement.